Brought to you by 
MedImmune boosts its early-stage oncology pipeline with $225mm Amplimmune buy
24 Aug 2020
Executive Summary
AstraZeneca PLC’s MedImmune LLC has agreed to pay $225mm up front, plus up to $275mm in development earn-outs, to acquire Amplimmune Inc., a private six-year-old company developing immune-mediating cancer therapies (IMT-C).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune boosts its early-stage oncology pipeline with $225mm Amplimmune buy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice